Compugen Ltd. (CGEN) is currently priced at $2.78, reflecting a decrease of 14 cents (-4.79%) from the previous close of $2.92. The trading volume stands at $240,723, representing a 68.23% increase relative to the average volume.
CGEN's latest quarterly earnings report is expected to be released on Sunday, March 1st, with a consensus estimate EPS of 0.05.
The company generated a free cash flow of $31.33 million, with a net change in cash of $90.60 million. Notable cash activities include acquisitions netting $1,000 and issuing common stock worth $10.61 million.
In the last reporting period, CGEN reported revenue of $67.33 million, resulting in a gross profit of $63.80 million. Operating income stood at $56 million, with a net income of $56.84 million, translating to an EPS of 60 cents.
Key ratios for CGEN include a gross profit margin of 94.75%, return on equity of 55.33%, and a price-to-sales ratio of 2.14.
The balance sheet shows total assets of $156.87 million, of which cash and cash equivalents account for $90.60 million. Total liabilities amount to $54.14 million, resulting in net debt of -$87.64 million.
This real-time financial snapshot underscores CGEN's price decline, increased trading volume, and upcoming earnings report, providing insights into its financial health and performance.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.